HealthLinx Says New OvPlex Algorithm Beats CA125 in Avoiding False Positives
July 06, 2012
HealthLinx Says New OvPlex Algorithm Beats CA125 in Avoiding False Positives
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mane Cancer Dx Requests Extension of Deadlines Related to Healthlinx OvPlex Deal
December 7, 2012 / ProteoMonitor - UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Healthlinx Shareholders Approve Sale of OvPlex Dx to Mane Cancer Diagnostics
October 5, 2012 / ProteoMonitor - HealthLinx Announces Data Demonstrating Potential of Protein Marker as Ovarian Cancer Prognostic
February 17, 2012 / ProteoMonitor - Healthlinx Signs $9M Financing Deal to Drive Expansion of OvPlex into US
December 16, 2011 / ProteoMonitor